CA-AQUA-LUNG
11.9.2019 00:27:02 CEST | Business Wire | Press release
Aqua Lung , the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, has appointed Mr. Matthieu Bazil as its new CEO, effective immediately. Mr. Bazil will be based from the Aqua Lung Group offices in Carros, France.
Bazil takes the helm as Aqua Lung continues on a path of global leadership in developing and bringing to market the best in scuba, swim, snorkel, and recreational paddle sport products. Bazil, a passionate watersports enthusiast and scuba diver, comes to Aqua Lung after highly successful engagements at Fox Racing, Oxbow, Boardriders Inc. (with global leadership roles at both DC Shoes and Quiksilver), and key account management with adidas.
“I have worked in the sports industry all my life and have sought out brands that are authentic and credible in their space and leaders in their industry. Aqua Lung fits this definition perfectly, being the pioneer of scuba diving, and each brand of the portfolio being the most authentic and credible player in their segment,” said Mr. Bazil.
The Aqua Lung Group is fully committed to evolving and innovating the absolute best products to inspire every type of water exploration, led by scuba brands Aqua Lung and Apeks Diving. The Group is also heavily invested in the world of swimming, with Aqua Sphere and a longstanding partnership with Michael Phelps around the MP Brand swimming line for competitive swimmers and triathletes.
“We will rely most on the strength of our assets, whether it’s the best to ever get in the pool in Michael Phelps, or the first family of the Oceans with Philippe and Ashlan Cousteau -- combining these iconic personalities with our incredibly capable internal teams and brands, we will push forward with truly remarkable next-generation products built by our dedicated experts worldwide. There is much on the horizon for the Aqua Lung Group and it is my honor to be joining this talented team,” concluded Mr. Bazil.
About the Aqua Lung Group
Aqua Lung pioneered the creation of modern diving equipment in 1943 when Captain Jacques-Yves Cousteau teamed with Emile Gagnan to develop the first “aqua-lung” that made underwater exploration possible. Today, the brand continues to be the leading global designer and manufacturer of dive and water sports gear. With a deep commitment to quality, research and testing, Aqua Lung has revolutionized the scuba diving experience by setting industry standards for scuba equipment in technology, comfort, safety and design. The company’s rich history as an expert in the dive and water sports industry has led to the demand of Aqua Lung equipment for recreational, swim, technical and military applications in more than 100 countries around the world, under the brand names Aqua Lung, MP Michael Phelps, Aqua Sphere, Apeks, O.ME.R, U.S. Divers, and Stohlquist. For more information, visit www.AquaLung.com , http://www.Facebook.com/AquaLungDivers .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910006162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release
The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled
Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release
India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom